web analytics

Description

A patient receiving certain anticonvulsant drugs may develop a drug hypersensitivity reaction that can be life-threatening. The presence of clinical findings justifies drug discontinuation pending exclusion of other causes.


 

Drugs involved: primarily phenytoin, carbamazepine, phenobarbital

 

Very common clinical findings (affect 90+ percent):

(1) fever (38 to 40°C, may be spiking) with negative blood, urine and CSF cultures

(2) skin rash (patchy macular erythema, maculopapular, erythroderma, exfolliative dermatitis; often pruritic)

 

Common clinical findings (affect 50-70%)

(1) lymphadenopathy with biopsy showing benign lymphoid hyperplasia or pseudolymphoma

(2) hepatitis (with or without hepatosplenomegaly)

(3) multi-organ involvement (combinations of cardiac, gastrointestinal, CNS, pulmonary, renal)

(4) hematologic abnormality (eosinophilia, atypical lymphocytosis, Coombs-negative hemolytic anemia, thrombocytopenia, neutrophilia or neutropenia)

 

Occasional clinical findings (10-25%):

(1) facial or periorbital edema

(2) myalgia and/or arthralgias

(3) interstitial nephritis

(4) pharyngitis

 

Infrequent clinical findings:

(1) anorexia

(2) carditis

(3) conjunctivitis

(4) encephalitis

(5) myositis and/or rhabdomyolysis

(6) pneumonitis

(7) lymphocytic thyroiditis

(8) mucositis

 

Confirmation of diagnosis:

(1) exclusion of other causes (infection, autoimmune, toxic)

(2) recurrence of symptoms on re-exposure (because of the risks entailed, this often is not performed)

 


To read more or access our algorithms and calculators, please log in or register.